SynthesisBMC neurology2025
Comparative safety and efficacy of 0.6 mg/kg versus 0.9 mg/kg alteplase in acute ischemic stroke: a systematic review and meta-analysis.
Synthesis in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlteplase is the standard thrombolytic therapy for acute ischemic stroke, with 0.9 mg/kg as the widely recommended dose. However, a lower dose of 0.6 mg/kg has been used, particularly in some populations, to reduce bleeding risk. We conducted a meta-analysis to compare the efficacy and safety of 0.6 mg/kg versus 0.9 mg/kg alteplase.
methodsA systematic search identified 11 observational studies and randomized controlled trials totaling 6,148 patients who received either low-dose or standard-dose alteplase within 4.5 h of symptom onset. Outcomes evaluated included symptomatic intracranial hemorrhage (sICH), any intracranial hemorrhage (ICH), 90-day mortality, in-hospital mortality, and functional outcomes measured by the modified Rankin Scale (mRS). Random-effects meta-analyses generated pooled odds ratios (OR) with 95% confidence intervals (CI).
resultsLow-dose alteplase was associated with a significantly lower risk of sICH compared to standard-dose (OR 0.51, 95% CI 0.35-0.76, p = 0.0008). No significant differences were observed in any ICH (OR 1.00, 95% CI 0.84-1.19, p = 0.99), 90-day mortality (OR 0.86, 95% CI 0.71-1.04, p = 0.12), or functional independence defined by mRS 0-1 at 90 days (OR 0.90, 95% CI 0.80-1.01, p = 0.09). Heterogeneity was low to moderate across outcomes.
conclusionLow-dose alteplase may reduce the risk of symptomatic hemorrhage without compromising mortality or functional recovery. These findings support consideration of dose individualization in clinical practice, warranting further prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.